Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Meridian Small Cap Growth Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Meridian Small Cap Growth returned 21.54% in Q2 2026, trailing its benchmark's 25.71% as quality-oriented, lower-beta positioning faced headwinds in a risk-on rally favoring high-beta stocks. Strong stock selection partially offset factor drag, led by medical device and biotech winners including Hinge Health, Definium Therapeutics, and Veracyte."
The Meridian Small Cap Growth Fund returned 21.54% in Q2 2026, trailing the Russell 2000 Growth Index's 25.71% return due to factor headwinds from its quality-oriented, lower-beta positioning during a risk-on rally that favored high-beta and high-momentum stocks. Stock selection contributed positively, with top contributors including Hinge Health (musculoskeletal care platform that beat earnings and raised guidance), Definium Therapeutics (clinical-stage biotech with positive Phase 3 results in major depressive disorder), and Veracyte (genomic diagnostics with strong volume growth). Detractors included Tandem Diabetes Care (insulin pump maker facing reimbursement transition uncertainty) and two private positions marked lower in a cautious valuation environment. The fund's investment approach emphasizes high-quality businesses with recurring revenue and sustainable competitive advantages, prioritizing risk management over return opportunity. Looking ahead, the manager monitors Iran conflict trajectory and energy prices as the most significant near-term uncertainty, alongside rising rates and inflation pressures, while noting constructive AI-related capital expenditure creating technology supply chain opportunities.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.